[1] Oda K, Uto H, Mawatari S, et al. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: A review of human studies. Clin J Gastroenterol, 2015, 8:1-9.
[2] 赵红, 谢雯. 非酒精性脂肪性肝病的中西医结合治疗现状.中国临床医生杂志, 2020, 48: 16-18.
[3] Leoni S, Tovoli F, Napoli L, et al. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol, 2018, 24: 3361-3373.
[4] Bohte AE, van Werven JR, Bipat S, et al. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: A meta-analysis. Eur Radiol, 2011, 21:87-97.
[5] Guo Z, Blake GM, Li K, et al. Liver fat content measurement with quantitative CT validated against MRI Proton density fat fraction: A prospective study of 400 healthy volunteers. Radiology, 2020, 294: 89-97.
[6] Lubner MG, Jones D, Kloke J, et al. CT texture analysis of the liver for assessing hepatic fibrosis in patients with hepatitis C virus. Br J Radiol, 2019, 92: 20180153.
[7] Pickhardt PJ, Graffy PM, Said A, et al. Multiparametric CT for noninvasive staging of hepatitis C virus-related liver fibrosis: Correlation with the histopathologic fibrosis score. AJR Am J Roentgenol, 2019, 212:547-553.
[8] Grt? K, Pacho R, Gr?t M, et al. Impact of body composition on the risk of hepatocellular carcinoma recurrence after liver transplantation. J Clin Med, 2019, 8: 1672-1684.
[9] Zhou CJ, Cheng YF, Xie LZ, et al. Metabolic syndrome, as defined based on parameters including visceral fat area, predicts complications after surgery for rectal cancer. Obes Surg, 2020, 30: 319-326.
[10] Weston AD, Korfiatis P, Kline TL, et al. Automated abdominal segmentation of CT scans for body composition analysis using deep learning. Radiology, 2019, 290:669-679.
[11] Di Martino M, Pacifico L, Bezzi M, et al. Comparison of magnetic resonance spectroscopy, proton density fat fraction and histological analysis in the quantification of liver steatosis in children and adolescents. World J Gastroenterol, 2016, 22: 8812-8819.
[12] 安梓铭, 冯琴.磁共振质子密度脂肪分数——一种具有潜力的非酒精性脂肪性肝炎临床试验替代终点.临床肝胆病杂志, 2021, 37:1445-1448.
[13] Gu J, Liu S, Du S, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: A meta-analysis. Eur Radiol, 2019, 29: 3564-3573.
[14] Middleton MS, Heba ER, Hooker CA, et al. Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis. Gastroenterology, 2017, 153:753-761.
[15] Wildman-Tobriner B, Middleton MM, Moylan CA, et al. Association between magnetic resonance imaging-proton density fat fraction and liver histology features in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis. Gastroenterology, 2018, 155:1428-1435.
[16] Idilman IS, Aniktar H, Idilman R, et al. Hepatic steatosis: Quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology, 2013, 267: 767-775.
[17] Chang JS, Taouli B, Salibi N, et al. Opposed-phase MRI for fat quantification in fat-water phantoms with 1H MR spectroscopy to resolve ambiguity of fat or water dominance. AJR Am J Roentgenol, 2006, 187: W103-W106.
[18] 刘小玲, 阮君, 朱敬松. 磁共振波谱成像检测肝内脂肪浸润水平诊断非酒精性脂肪肝的价值.肝脏, 2021, 26:305-308.
[19] Chiang HJ, Chang WP, Chiang HW, et al. Magnetic resonance spectroscopy in living-donor liver transplantation. Transplant Proc, 2016, 48: 1003-1006.
[20] Singh S, Venkatesh SK, Loomba R, et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: A diagnostic accuracy systematic review and individual participant data pooled analysis. Eur Radiol, 2016, 26: 1431-1440.
[21] Liang Y, Li D. Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease: A pooled analysis of the diagnostic accuracy. BMC Gastroenterol, 2020, 20, 89-101.
[22] Srinivasa Babu A, Wells ML, Teytelboym OM, et al. Elastography in chronic liver disease: Modalities, techniques, limitations, and future directions. Radiographics, 2016, 36: 1987-2006.
[23] Chang W, Lee JM, Yoon JH, et al. Liver fibrosis staging with MR elastography: Comparison of diagnostic performance between patients with chronic hepatitis B and those with other etiologic causes. Radiology, 2016, 280: 88-97.
[24] Wang QB, Zhu H, Liu HL, et al. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Hepatology, 2012, 56: 239-247.
[25] Kromrey ML, Le Bihan D, Ichikawa S, et al. Diffusion-weighted MRI-based virtual elastography for the assessment of liver fibrosis. Radiology, 2020, 295: 127-135.
[26] Petzold G, Lasser J, Rühl J, et al. Diagnostic accuracy of B-mode ultrasound and Hepatorenal Index for graduation of hepatic steatosis in patients with chronic liver disease. PLoS ONE, 2020, 15: e0231044.
[27] 赵巧慧.非酒精性脂肪肝采用Fibro Touch诊断的临床效果评价.影像研究与医学应用, 2021, 5:24-25.
[28] Shen F, Zheng RD, Mi YQ, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol, 2014, 20: 4702-4711.
[29] Pu K, Wang Y, Bai S, et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: A systematic review and meta-analysis. BMC Gastroenterol, 2019, 19: 51-62.
[30] Runge JH, Smits LP, Verheij J, et al. MR Spectroscopy-derived proton density fat fraction is superior to controlled attenuation parameter for detecting and grading hepatic steatosis. Radiology, 2018, 286:547-556.
[31] Oeda S, Takahashi H, Imajo K, et al. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan? M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. J Gastroenterol, 2020, 55: 428-440.
[32] Petta S, Wong V W, Cammà C, et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology, 2017, 65:1145-1155.
[33] Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019, 156: 1717-1730.
[34] Cassinotto C, Boursier J, de Lédinghen V, et al. Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology, 2016, 63:1817-1827.
[35] Lee MS, Bae JM, Joo SK, et al. Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease. PLoS One, 2017, 12:e0188321.
[36] Leung VY, Shen J, Wong VW, et al. Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers: Comparison of shear-wave elastography and transient elastography with liver biopsy correlation. Radiology, 2013, 269, 910-918.
[37] Cassinotto C, Lapuyade B, Mouries A, et al. Non-invasive assessment of liver fibrosis with impulse elastography: cmparison of Supersonic Shear Imaging with ARFI and FibroScan?. J Hepatol, 2014, 61:550-557.
[38] Cruz-Jentoft AJ, Bahat, G, Bauer J, et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing, 2019, 48: 16-31.
[39] Bazzocchi A, Diano D, Albisinni U, et al. Liver in the analysis of body composition by dual-energy X-ray absorptiometry. Br J Radiol, 2014, 87: 20140232.
[40] Petta S, Sebastiani G, Viganò M, et al. Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Clin Gastroenterol Hepatol, 2021, 19:806-815. |
